Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ALDX – Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.
ALDX
$5.81
Name : Aldeyra Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $348,864,352.00
EPSttm : -0.85
finviz dynamic chart for ALDX
Aldeyra Therapeutics, Inc.
$5.81
1.19%
$0.07

Float Short %

8.65

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

-0.02

EPS Last/This Y

0.28

EPS This/Next Y

1.25

Price

5.81

Target Price

9.5

Analyst Recom

1

Performance Q

158.22

Relative Volume

1

Beta

0.77

Ticker: ALDX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ALDX5.160.240.8820989
2025-07-28ALDX5.320.250.1021051
2025-07-29ALDX5.090.251.0021070
2025-07-30ALDX5.050.250.1021083
2025-07-31ALDX4.990.250.1821104
2025-08-01ALDX4.80.250.4221114
2025-08-04ALDX5.070.230.0221159
2025-08-05ALDX5.160.230.0821327
2025-08-06ALDX5.220.238.0021521
2025-08-07ALDX5.180.190.0120924
2025-08-08ALDX5.260.190.1520888
2025-08-11ALDX5.240.190.0820946
2025-08-12ALDX5.350.191.2020939
2025-08-13ALDX5.380.191.6220885
2025-08-14ALDX5.30.200.0620965
2025-08-15ALDX5.380.201.3321023
2025-08-18ALDX5.450.220.0520295
2025-08-19ALDX5.590.220.0120360
2025-08-20ALDX5.620.221.3420390
2025-08-21ALDX5.880.220.2420454
2025-08-22ALDX5.80.230.0721441
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ALDX5.1733.0- -0.68
2025-07-28ALDX5.3033.0- -0.68
2025-07-29ALDX5.0933.0- -0.68
2025-07-30ALDX5.0533.0- -0.68
2025-07-31ALDX4.9933.0- -0.68
2025-08-01ALDX4.8133.0- -0.68
2025-08-04ALDX5.0833.0- -0.68
2025-08-05ALDX5.1633.0- -0.68
2025-08-06ALDX5.2133.0- -0.68
2025-08-07ALDX5.1733.0- -0.68
2025-08-08ALDX5.2633.0- -0.68
2025-08-11ALDX5.2533.0- -0.68
2025-08-12ALDX5.3532.0- -0.68
2025-08-13ALDX5.3732.0- -0.68
2025-08-14ALDX5.3032.0- -0.68
2025-08-15ALDX5.3932.0- -0.66
2025-08-18ALDX5.4537.0- -0.66
2025-08-19ALDX5.6037.0- -0.66
2025-08-20ALDX5.6237.0- -0.66
2025-08-21ALDX5.8737.0- -0.66
2025-08-22ALDX5.8137.0- -0.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ALDX-66.03-14.277.96
2025-07-28ALDX-66.03-12.517.96
2025-07-29ALDX-66.03-12.517.96
2025-07-30ALDX-66.03-12.517.96
2025-07-31ALDX-66.03-12.517.96
2025-08-01ALDX-66.03-12.517.96
2025-08-04ALDX-66.03-11.867.96
2025-08-05ALDX-66.03-11.867.96
2025-08-06ALDX-66.03-11.867.96
2025-08-07ALDX-66.03-11.867.96
2025-08-08ALDX-66.03-11.867.96
2025-08-11ALDX-66.03-11.757.96
2025-08-12ALDX-66.03-11.758.66
2025-08-13ALDX-66.03-11.758.66
2025-08-14ALDX-66.18-11.758.66
2025-08-15ALDX-66.16-11.758.66
2025-08-18ALDX-66.16-12.428.65
2025-08-19ALDX-66.55-12.428.65
2025-08-20ALDX-66.55-12.428.65
2025-08-21ALDX-66.55-12.428.65
2025-08-22ALDX-66.55-12.428.65
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.16

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

-66.55

Institutional Transactions

-12.42

Beta

0.77

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

24

Fair Value

Quality Score

10

Growth Score

22

Sentiment Score

97

Actual DrawDown %

63.6

Max Drawdown 5-Year %

-90.4

Target Price

9.5

P/E

Forward P/E

39.17

PEG

P/S

P/B

6.31

P/Free Cash Flow

EPS

-0.85

Average EPS Est. Cur. Y​

-0.66

EPS Next Y. (Est.)

0.59

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1

Return on Equity vs Sector %

-116.2

Return on Equity vs Industry %

-103.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

Aldeyra Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 8
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
stock quote shares ALDX – Aldeyra Therapeutics, Inc. Stock Price stock today
news today ALDX – Aldeyra Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALDX – Aldeyra Therapeutics, Inc. yahoo finance google finance
stock history ALDX – Aldeyra Therapeutics, Inc. invest stock market
stock prices ALDX premarket after hours
ticker ALDX fair value insiders trading